Tirzepatide News
Every article we’ve published on Tirzepatide, newest first — 3 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
Semaglutide Muscle Loss Study Joins New Trials on Lean Mass
Three separate research entries indexed in the past week — a longitudinal semaglutide muscle loss study, a review of skeletal muscle health during incretin-based therapy, and a newly posted Phase 4 trial — all converge on the same unanswered question. For anyone tracking a GLP-1 protocol, lean mass is moving from forum speculation to formal endpoint.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Tirzepatide Combination Therapy Trials: Four New Add-On Studies
Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.